Compass Pathways has announced that its investigational psilocybin therapy, COMP360, met the primary endpoint in its Phase 3 ...

A single dose of a synthetic psilocybin was found to improve symptoms in patients with treatment-resistant depression.

Compass Pathways took a 50% on June 23 hit after a lukewarm trial, but long-term bulls see upside in psychedelics.

An Iowa lawmaker who had pushed for the passage Gov. Kim Reynolds’ decision to veto a bill pertaining to the psychoactive ...

Though caution is required when the data haven't been published, it could be a landmark in the drug's journey toward FDA ...

Compass Pathways plc downgraded to Hold after mixed trial results. Explore upcoming catalysts in depression treatment and ...

The UK-based firm earlier announced that it had met the primary endpoint in the ongoing 258-patient Phase III COMP005 trial, ...

Stifel said the plunge in Compass Pathways shares was “significantly overdone” after data showed that the company’s COMP360 ...

Fintel reports that on June 23, 2025, Evercore ISI Group downgraded their outlook for COMPASS Pathways plc - Depositary ...

A single dose of a synthetic form of psilocybin is safe and clinically meaningful in reducing treatment-resistant depression, ...

Although the company withheld detailed findings from the study of treatment-resistant depression, analysts at Stifel called ...

COMPASS Pathways Plc (NASDAQ:CMPS) stock is trading lower on Monday. The company announced it reached its primary endpoint in ...